Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Hoffmann-La Roche
Jazz Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Novartis
Valent Technologies, LLC
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Virginia
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Bristol-Myers Squibb
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Oncurious NV
Barbara Ann Karmanos Cancer Institute
Lumos Pharma
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Washington University School of Medicine
Medical College of Wisconsin
Stanford University
Wake Forest University Health Sciences
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Pediatric Brain Tumor Consortium
University of Iowa
University of Southern California
University of Iowa